Strata Oncology Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 138

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $90M

  • Investors
  • 12

Strata Oncology General Information

Description

Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer. The company partners with major healthcare systems across the country, who systematically send their cancer patient's biopsies to high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials, enabling healthcare providers to provide actionable insight to the lives of cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Other Industries
Laboratory Services (Healthcare)
Biotechnology
Primary Office
  • 8192 Jackson Road
  • Suite A
  • Ann Arbor, MI 48103
  • United States
+1 (734) 000-0000

Strata Oncology Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Strata Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 28-Jul-2021 $90M 00000 00000 Completed Generating Revenue
3. Later Stage VC 04-Nov-2020 000 0000 Completed Generating Revenue
2. Early Stage VC (Series B) 23-May-2018 $26M $38M 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 02-Jun-2016 $12M $12M 0000 Completed Startup
To view Strata Oncology’s complete valuation and funding history, request access »

Strata Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series C-1 000,000 00.000000 00 000.00 000.00 00 000.00 0.000
Series B 2,625,918 $0.000010 8% $9.9 $9.9 1x $9.9 23.29%
Series A 3,054,529 $0.000010 8% $4.04 $4.04 1x $4.04 27.09%
To view Strata Oncology’s complete cap table history, request access »

Strata Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer. The co
Decision/Risk Analysis
Ann Arbor, MI
138 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000000000000
Wuxi, China
00000
00000000 00000

000 (0

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000000
Auburndale, MA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Strata Oncology Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GeneCast Biotechnology Private Equity-Backed Wuxi, China 00000 00000000 00000
000 (0000000000000 Venture Capital-Backed Auburndale, MA 00 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed Seattle, WA 000 00000 00000000 00000
000000 Venture Capital-Backed Boston, MA 000 00000 00000000000 00000
0000000 Venture Capital-Backed Houston, TX 00 00000 0000000000 0 00000
You’re viewing 5 of 21 competitors. Get the full list »

Strata Oncology Patents

Strata Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3899537-A4 Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer Pending 19-Dec-2018 00000000000 0
AU-2019403339-A1 Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer Pending 19-Dec-2018 0000000000
CA-3124471-A1 Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer Pending 19-Dec-2018 0000000000
EP-3899537-A1 Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer Pending 19-Dec-2018 0000000000
US-20220081724-A1 Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer Pending 19-Dec-2018 C12Q1/6886
To view Strata Oncology’s complete patent history, request access »

Strata Oncology Executive Team (11)

Name Title Board Seat Contact Info
Daniel Rhodes Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Matthew Martin Chief Financial Officer
Catherine Sazdanoff JD Chief Business Development Officer, Chief Compliance Officer & Chief Legal Officer
Jennifer Reyntjes Chief People Officer
Mark Szewczyk Chief Commercial Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Strata Oncology Board Members (11)

Name Representing Role Since
Amy Kobe Baird Capital Board Member 000 0000
Christopher O'Donnell Ph.D Pfizer Ventures Board Member 000 0000
Dan Kidle Arboretum Ventures Board Observer 000 0000
Daniel Rhodes Ph.D Strata Oncology Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Jan Garfinkle Arboretum Ventures Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Strata Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Strata Oncology Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Highside Capital Management Family Office Minority 000 0000 000000 0
Monashee Investment Management Hedge Fund Minority 000 0000 000000 0
Wellington Management Asset Manager Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »